Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Int J Mol Sci ; 22(19)2021 Sep 23.
Article in English | MEDLINE | ID: mdl-34638592

ABSTRACT

The development of neuropathy and of mood alterations is frequent after chemotherapy. These complications, independent from the antitumoral mechanism, are interconnected due to an overlapping in their processing pathways and a common neuroinflammatory condition. This study aims to verify whether in mice the treatment with the proteasome inhibitor bortezomib (BTZ), at a protocol capable of inducing painful neuropathy, is associated with anxiety, depression and supraspinal neuroinflammation. We also verify if the therapeutic treatment with the antagonist of the prokineticin (PK) system PC1, which is known to contrast pain and neuroinflammation, can prevent mood alterations. Mice were treated with BTZ (0.4 mg/kg three times/week for 4 weeks); mechanical allodynia and locomotor activity were evaluated over time while anxiety (dark light and marble burying test), depression (sucrose preference and swimming test) and supraspinal neuroinflammation were checked at the end of the protocol. BTZ treated neuropathic mice develop anxiety and depression. The presence of mood alterations is related to the presence of neuroinflammation and PK system activation in prefrontal cortex, hippocampus and hypothalamus with high levels of PK2 and PKR2 receptor, IL-6 and TNF-α, TLR4 and an upregulation of glial markers. PC1 treatment, counteracting pain, prevented the development of supraspinal inflammation and depression-like behavior in BTZ mice.


Subject(s)
Affect/drug effects , Bortezomib/pharmacology , Proteasome Inhibitors/pharmacology , Vascular Endothelial Growth Factor, Endocrine-Gland-Derived/metabolism , Animals , Anxiety/drug therapy , Anxiety/metabolism , Biomarkers/metabolism , Cytokines/metabolism , Depression/drug therapy , Depression/metabolism , Disease Models, Animal , Hippocampus/drug effects , Hippocampus/metabolism , Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Hypothalamus/drug effects , Hypothalamus/metabolism , Inflammation/drug therapy , Inflammation/metabolism , Locomotion/drug effects , Male , Mice , Mice, Inbred C57BL , Pain/drug therapy , Pain/metabolism , Peripheral Nervous System Diseases/drug therapy , Peripheral Nervous System Diseases/metabolism , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Receptors, G-Protein-Coupled/metabolism , Up-Regulation/drug effects
2.
Front Immunol ; 11: 2119, 2020.
Article in English | MEDLINE | ID: mdl-33072073

ABSTRACT

Neurotoxicity is a common side effect of chemotherapeutics that often leads to the development of chemotherapy-induced peripheral neuropathy (CIPN). The peptide Prokineticin 2 (PK2) has a key role in experimental models of CIPN and can be considered an insult-inducible endangering mediator. Since primary afferent sensory neurons are highly sensitive to anticancer drugs, giving rise to dysesthesias, the aim of our study was to evaluate the alterations induced by vincristine (VCR) and bortezomib (BTZ) exposure in sensory neuron cultures and the possible preventive effect of blocking PK2 signaling. Both VCR and BTZ induced a concentration-dependent reduction of total neurite length that was prevented by the PK receptor antagonist PC1. Antagonizing the PK system also reduced the upregulation of PK2, PK-R1, TLR4, IL-6, and IL-10 expression induced by chemotherapeutic drugs. In conclusion, inhibition of PK signaling with PC1 prevented the neurotoxic effects of chemotherapeutics, suggesting a promising strategy for neuroprotective therapies against the sensory neuron damage induced by exposure to these drugs.


Subject(s)
Antineoplastic Agents/toxicity , Bortezomib/toxicity , Gastrointestinal Hormones/antagonists & inhibitors , Nerve Tissue Proteins/antagonists & inhibitors , Neuropeptides/antagonists & inhibitors , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes/prevention & control , Sensory Receptor Cells/drug effects , Triazines/pharmacology , Vincristine/toxicity , Animals , Cells, Cultured , Dose-Response Relationship, Drug , Down-Regulation , Drug Evaluation, Preclinical , Gastrointestinal Hormones/physiology , Gene Expression Regulation/drug effects , Male , Mice , Mice, Inbred C57BL , Nerve Tissue Proteins/physiology , Neurites/drug effects , Neurites/ultrastructure , Neuroimmunomodulation/drug effects , Neuropeptides/physiology , Neuroprotective Agents/therapeutic use , RNA, Messenger/biosynthesis , Sensory Receptor Cells/physiology , Sensory Receptor Cells/ultrastructure , Triazines/therapeutic use
3.
Front Immunol ; 10: 2914, 2019.
Article in English | MEDLINE | ID: mdl-31921173

ABSTRACT

Suppression of the immune system has been constantly reported in the last years as a classical side effect of opioid drugs. Most of the studies on the immunological properties of opioids refer to morphine. Although morphine remains the "reference molecule," other semisynthetic and synthetic opioids are frequently used in the clinical practice. The primary objective of this review is to analyze the available literature on the immunomodulating properties of opioid drugs different from morphine in preclinical models and in the human. A search strategy was conducted in PubMed, Embase, and the Cochrane databases using the terms "immunosuppression," "immune system," "opioids," "Natural killer cells," "cytokines," and "lymphocytes." The results achieved concerning the effects of fentanyl, methadone, oxycodone, buprenorphine, remifentanil, tramadol, and tapentadol on immune responses in animal studies, in healthy volunteers and in patients are reported. With some limitations due to the different methods used to measure immune system parameters, the large range of opioid doses and the relatively scarce number of participants in the available studies, we conclude that it is not correct to generalize immunosuppression as a common side effect of all opioid molecules.


Subject(s)
Analgesics, Opioid/pharmacology , Immunologic Factors/pharmacology , Analgesics, Opioid/chemistry , Analgesics, Opioid/therapeutic use , Animals , Clinical Studies as Topic , Drug Evaluation, Preclinical , Humans , Immunologic Factors/chemistry , Immunologic Factors/therapeutic use
4.
J Neuroimmune Pharmacol ; 10(2): 371-9, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25875136

ABSTRACT

Cannabis use is frequent among adolescents. Its main component, delta-9-tetrahydrocannabinol (THC), affects the immune system. We recently demonstrated that chronic exposure of adolescent mice to THC suppressed immunity immediately after treatment but that after a washout period THC induced a long-lasting opposite modulation towards a proinflammatory and T-helper-1 phenotype in adulthood. The main objective of this study was to investigate whether the same effect was also present in brain regions such as the hypothalamus and hippocampus. Thirty-three-day-old adolescent and 80-day-old adult male mice were used. Acute THC administration induced a similar reduction of macrophage proinflammatory cytokines and an IL-10 increase in adult and adolescent mice. THC did not affect brain cytokines in adult mice, but a proinflammatory cytokine decrease was evident in the adolescent brain. A similar effect was present in the hypothalamus and hippocampus after 10 days' THC administration. In contrast, when brain cytokines were measured 47 days after the final THC administration, we observed an inverted effect in adult mice treated as adolescents, i.e., IL-1ß and TNF-α increased and IL-10 decreased, indicating a shift toward neuroinflammation. These data suggest that THC exposure in adolescence has long-lasting effects on brain cytokines that parallel those present in the periphery. This modulation may affect vulnerability to immune and behavioural diseases in adulthood.


Subject(s)
Cytokines/biosynthesis , Dronabinol/administration & dosage , Hippocampus/metabolism , Hypothalamus/metabolism , Macrophages/metabolism , Age Factors , Animals , Cells, Cultured , Hippocampus/drug effects , Hypothalamus/drug effects , Inflammation Mediators/metabolism , Macrophages/drug effects , Male , Mice , Mice, Inbred BALB C , Time Factors
5.
J Neurochem ; 107(1): 230-40, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18691380

ABSTRACT

There is great interest in soy isoflavones as alternatives to endogenous estrogens not only in hormonal pathologies, but also in inflammatory, neurodegenerative diseases, and pain. We investigated the effect of the isoflavone genistein on neuropathic pain. Genistein binds estrogen receptors (ER) with higher affinity for the ERbeta particularly expressed in neuronal and immune cells. Neuropathy was induced in mice by means of chronic sciatic nerve constriction, and the subcutaneous administration of genistein from the third day after the lesion reversed pain hypersensitivity in a time- and dose-dependent manner. This effect may have been due to the activation of classical nuclear receptor and/or anti-oxidant, anti-inflammatory, and immunomodulating properties of genistein. The fact that a specific ERbeta antagonist prevented both its anti-allodynic and anti-hyperalgesic action, whereas a specific ERalpha antagonist was ineffective and a non-selective ER antagonist only reversed the anti-allodynic effect, suggests the involvement of ERbeta. Antioxidant effects are also involved as the anti-nociceptive dose reversed the increase in reactive oxygen species and malondialdehyde in injured paw tissues, and increased the activity of anti-oxidant enzymes. The phytoestrogen had immunomodulatory and anti-inflammatory activities as it reduced peripheral and central nuclear factor-kappaB, nitric oxide system and pro-inflammatory cytokine over-activation. Taken together, our results suggest that genistein could ameliorate painful neuropathy by multiple mechanisms.


Subject(s)
Genistein/pharmacology , Inflammation/drug therapy , Oxidative Stress/drug effects , Peripheral Nervous System Diseases/drug therapy , Sciatic Neuropathy/drug therapy , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacology , Antioxidants/therapeutic use , Chronic Disease/drug therapy , Disease Models, Animal , Dose-Response Relationship, Drug , Ganglia, Spinal/drug effects , Ganglia, Spinal/metabolism , Ganglia, Spinal/physiopathology , Genistein/therapeutic use , Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Inflammation/metabolism , Inflammation/physiopathology , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Ligation , Male , Mice , Mice, Inbred C57BL , Neurons, Afferent/drug effects , Neurons, Afferent/metabolism , Nociceptors/drug effects , Nociceptors/metabolism , Nociceptors/physiopathology , Oxidative Stress/physiology , Peripheral Nervous System Diseases/metabolism , Peripheral Nervous System Diseases/physiopathology , Phytoestrogens/pharmacology , Phytoestrogens/therapeutic use , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Receptors, Estrogen/drug effects , Receptors, Estrogen/metabolism , Sciatic Neuropathy/metabolism , Sciatic Neuropathy/physiopathology , Glycine max/chemistry , Treatment Outcome
6.
Eur J Pain ; 12(3): 284-92, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17664076

ABSTRACT

The anti-inflammatory and analgesic properties of different bisphosphonates have been demonstrated in both animal and human studies. Ibandronate is a third-generation bisphosphonate effective in managing different types of bone pain. In this study we investigated its effects in a standard pre-clinical model of inflammatory pain. We evaluated the effects of a single injection of different doses (0.5, 1.0, and 2.0 mg/kg i.p.) of ibandronate on inflammatory oedema and cutaneous hyperalgesia produced by the intraplantar injection of complete Freund's adjuvant (CFA) in the rat hind-paw. In addition, we measured the effects of this drug (1.0 mg/kg i.p.) on hind-paw levels of different pro-inflammatory mediators (PGE-2, SP, TNF-alpha, and IL-1beta). We also measured the levels of SP protein and of its mRNA in the ipsilateral dorsal root ganglia (DRG). Ibandronate proved able to reduce the inflammatory oedema, the hyperalgesia to mechanical stimulation, and the levels of SP in the inflamed tissue as measured 3 and 7 days following CFA-injection. This drug significantly reduced the levels of TNF-alpha and IL-1beta only on day 7. On the other hand, the levels of PGE-2 in the inflamed hind-paw were unaffected by the administration of this bisphosphonate. Finally, ibandronate blocked the overexpression of SP mRNA in DRG induced by CFA-injection in the hind-paw. These data help to complete the pharmacodynamic profile of ibandronate, while also suggesting an involvement of several inflammatory mediators, with special reference to substance P, in the analgesic action of this bisphosphonate.


Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cytokines/analysis , Diphosphonates/therapeutic use , Edema/drug therapy , Hyperalgesia/drug therapy , Inflammation/drug therapy , Substance P/analysis , Animals , Chronic Disease , Dinoprostone/analysis , Drug Evaluation, Preclinical , Edema/chemically induced , Foot , Freund's Adjuvant/toxicity , Ganglia, Spinal/chemistry , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Ibandronic Acid , Inflammation/chemically induced , Inflammation/physiopathology , Interleukin-1beta/analysis , Male , RNA, Messenger/analysis , Rats , Rats, Sprague-Dawley , Substance P/biosynthesis , Substance P/genetics , Tumor Necrosis Factor-alpha/analysis
7.
Brain Behav Immun ; 20(6): 546-51, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16469481

ABSTRACT

The effect of Panax ginseng C.A. Meyer G115 on inflammatory cytokine production and toll-like receptor 4 (TLR4) RNA expression was examined in mice during 4 weeks of swimming stress. Mice were assigned to four groups: (1) control (no exercise); (2) control-G115 (25 mg/kg/day p.o.); (3) stress (kept swimming for 60 min daily); and (4) stress-G115 (25 mg/kg/day p.o. and kept swimming for 60 min daily). Peritoneal macrophages were collected at rest each week. RNA was extracted and processed for real-time PCR. An aliquot of macrophages was lipopolysaccharide (LPS)-stimulated for TNF-alpha and IL-1beta production. Different expression patterns between untreated and treated groups, and between TLR2 and TLR4 were found. High levels of TLR4 expression in the control-G115 group were detectable significantly at the first, and at the second week (P<.01 and P<.001, respectively). In the stress group, TLR4 showed a peak at the first week (P<.001 vs. controls) and then decreased gradually. In the stress-G115 group, the levels of TLR4 expression increased gradually at the second week (P<.001 vs. controls) with a peak at the third week (P<.001). Levels of TLR4 expression at the fourth week had returned to the basal level. Levels of TLR2 expression were not affected by treatment in all groups. A significant increase of LPS-stimulated IL-1beta and TNF-alpha concentrations was present in trained animals with similar patterns of TLR4 expression. These results support the hypothesis that enhancement of the production of pro-inflammatory cytokine can be linked to an increased expression of TLR4 on macrophages. Moreover, G115 increases the expression of TLR4 and the release of cytokines with a different pattern compared to the stressed alone group.


Subject(s)
Macrophages/drug effects , Panax , Physical Exertion/physiology , Plant Extracts/pharmacology , Stress, Physiological/immunology , Toll-Like Receptor 4/drug effects , Analysis of Variance , Animals , Cytokines , Interleukin-1beta/immunology , Interleukin-1beta/metabolism , Lipopolysaccharides/immunology , Macrophages/metabolism , Male , Mice , Mice, Inbred BALB C , Plants, Medicinal , RNA/analysis , Random Allocation , Statistics, Nonparametric , Stress, Physiological/metabolism , Swimming/physiology , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism
8.
Brain Res ; 1001(1-2): 78-86, 2004 Mar 19.
Article in English | MEDLINE | ID: mdl-14972656

ABSTRACT

Behavioral, hormonal and neuronal responses to prolonged exposure to the volatile components of essential oil (EO) extracted from citrus lemon were investigated in male and female rats. Animals were exposed to the lemon essence for 2 weeks while in their cage. Anxiety was then determined with the elevated plus-maze apparatus while nociception was evaluated with a phasic thermal pain stimulus (plantar test) and with a chemical pain stimulus (formalin test). At the end of the experimental sessions, brain areas were dissected to measure beta-endorphin (beta-EP) concentrations in the hypothalamus and periaqueductal gray matter (PAG). Blood samples were collected to determine corticosterone plasma levels. In both sexes, prolonged EO exposure decreased the time spent in the open arms of the plus-maze apparatus. EO-exposed males and females showed higher thermal nociceptive thresholds than controls when tested with the plantar test apparatus. EO exposure induced female-specific decreases in formalin-induced pain behaviors during the formalin test. beta-EP concentrations in the hypothalamus and PAG were affected by EO. Corticosterone was lower in EO-exposed animals of both sexes than in their controls. These results suggest that long-term exposure to lemon EO can induce significant, at times sex-specific, changes in neuronal circuits involved in anxiety and pain.


Subject(s)
Citrus/chemistry , Hypothalamus/drug effects , Maze Learning/drug effects , Oils, Volatile/pharmacology , Pain Threshold/drug effects , Periaqueductal Gray/drug effects , beta-Endorphin/metabolism , Analysis of Variance , Animals , Behavior, Animal/drug effects , Corticosterone/blood , Female , Formaldehyde , Male , Motor Activity/drug effects , Pain Measurement/drug effects , Plant Oils/pharmacology , Rats , Reaction Time/drug effects , Sex Factors , Time
SELECTION OF CITATIONS
SEARCH DETAIL